Spruce Biosciences (SPRB) is a high-conviction "10x" opportunity with a personal price target of $500, driven by a potential $100 million Priority Review Voucher sale and a strategic BLA filing delay to Q4. Sarepta Therapeutics (SRPT) offers a strong value play with a "valuation floor," as its market cap sits near annual revenue and its gene therapy pipeline could reach $3B in sales. Investors should consider shorting IonQ (IONQ), which is described as a "house of cards" with inorganic revenue growth and a lack of essential quantum technology. Avoid Super Micro Computer (SMCI) due to high-risk smuggling allegations and Bristol Myers Squibb (BMY) as it faces a massive patent cliff for Eliquis and a heavy debt load. For long-term exposure to the successor of GPUs, look toward Optical Computing players like Lumentum (LITE), Coherent (COHR), and Fabrinet (FN).

Super Micro Computer (SMCI)

• The stock is down 30% following reports of alleged GPU smuggling.
• Shkreli expressed skepticism regarding the surprise of the news, suggesting that market participants should have sensed issues with the company earlier.

Takeaways

• Bearish Sentiment: The significant price drop and smuggling allegations suggest a high-risk environment for the stock.
• Due Diligence: Investors should be wary of companies showing "too good to be true" growth or those involved in complex international hardware supply chains where regulatory oversight may be bypassed.

Planet Labs (PL)

• Reported record revenue and a record backlog in their latest earnings.
• The company provides satellite services, which Shkreli noted as a sector with increasing utility.

Takeaways

• Bullish Momentum: Record backlogs typically indicate strong future revenue visibility.
• Sector Interest: Space and satellite services are seeing "sympathy" moves alongside broader space industry developments (e.g., SpaceX).

Sarepta Therapeutics (SRPT)

• Described as a "value stock" with significant assets, including a valuable gene therapy plant.
• Financials: Approximately $1 billion in cash against $828 million in debt (positive net cash).
• Revenue: Trailing 12-month revenue is roughly $1.8B - $1.9B, with a market cap of $1.7B.
• Management Critique: Shkreli noted that $6 billion in capital has been invested into the company over time, but the market currently values the business at only $1.7B, suggesting poor historical management of capital.
• Product Data: Discussed the Elevidys (gene therapy) data; while some trials were not "statistically significant" (stat-sig), Shkreli believes the long-term data looks promising and could reach $2B - $3B in revenue.

Takeaways

• Investment Thesis: The stock is viewed as having a "floor" due to its valuation being close to its annual revenue and physical assets.
• Action: Potential for significant upside if the gene therapy pipeline gains broader FDA traction or hits revenue targets of $2B+.

Spruce Biosciences (SPRB)

• Shkreli is highly bullish, calling it a "no-brainer" and a "10x" opportunity.
• Timeline: The company delayed its BLA (Biologics License Application) filing from Q1 to Q4. Shkreli views this as a positive move to ensure a "good filing" rather than receiving a rejection (CRL).
• Valuation: Currently an $80 million market cap; Shkreli set a personal price target of $500 (currently trading around $60).
• Key Asset: The potential for a PRV (Priority Review Voucher) which can be sold to other pharma companies for approximately $100 million.

Takeaways

• High Conviction Long: This is identified as a top pick in the rare disease space.
• Risk/Reward: The delay to Q4 provides a longer window for accumulation, but investors must be patient for the drug launch next year.

IonQ (IONQ)

• Described as a "house of cards" and a "huge disaster."
• Revenue Analysis: Shkreli argues that much of their revenue is "acquired" through roll-ups of smaller companies rather than organic growth.
• Technical Critique: Claims the company lacks a "full stack" (no quantum storage, late on 100-qubit systems).
• Short Thesis: Shkreli suggests this is a prime short opportunity now that the "hype" has settled and the stock is "boring."

Takeaways

• Bearish Sentiment: High skepticism regarding the validity of their quantum computing claims.
• Action: Look for downside as the market realizes the revenue may be a "roll-up of garbage."

NVIDIA (NVDA)

• Acknowledged the incredible 73% revenue growth but questioned how long such a trajectory can be sustained.
• Market Position: Noted that margins are unlikely to shrink because the chips are extremely difficult to manufacture.
• Themes: Discussed the "Singularity" and the idea that AI is the "final invention," which keeps demand high.

Takeaways

• Neutral/Cautious Bullish: While the growth is historic, the massive market cap makes future exponential gains harder.
• Sector Play: Shkreli is looking at Optical Computing (specifically QCLS) as the eventual successor to GPUs due to lower energy usage.

Bristol Myers Squibb (BMY)

• Highly critical of current management; Shkreli stated the CEO should be fired.
• Debt Issues: The company has not reduced its heavy debt load over the last several years.
• Patent Cliff: Eliquis is going off-patent soon, which will create a massive revenue hole.
• Product Performance: Described several of their drugs (Tick2, Zeposia) as "dogs" (underperformers).

Takeaways

• Bearish Sentiment: Avoid until there is a change in management or a clearer strategy to handle the loss of patent protection for major drugs.

Investment Themes & Sector Insights

Optical Computing

• Theme: Moving from traditional electrical signals to light (optics) on chips to save energy and increase speed.
• Mentions: QCLS (Quantum Computing Inc.), Lumentum (LITE), Coherent (COHR), and Fabrinet (FN).
• Insight: Optics are "hot," but the market is already aware of this. Shkreli believes optical computing will eventually replace GPUs.

Quantum Computing

• Sentiment: Generally bearish on public companies like IonQ and D-Wave, calling them "crazy."
• Insight: Prefers private quantum companies or more "reasonable" players like Rigetti (RGTI), though still skeptical of the "quantum stack" existence.

Biotech/Rare Diseases

• Strategy: Focus on companies with PRVs (Priority Review Vouchers) and specialized rare disease treatments.
• Mentions: BioHaven (BHVN) (good management), Alumis (ALMS), and Sarepta (SRPT).